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AbstrACt 
Introduction Disruptions of proteasome and autophagy 
systems are central events in amyotrophic lateral sclerosis 
(ALS) and support the urgent need to find therapeutic 
compounds targeting these processes. The heat shock protein 
B8 (HSPB8) recognises and promotes the autophagy-mediated 
removal of misfolded mutant SOD1 and TDP-43 fragments 
from ALS motor neurons (MNs), as well as aggregating 
species of dipeptides produced in C9ORF72-related diseases. 
In ALS-SOD1 mice and in human ALS autopsy specimens, 
HSPB8 is highly expressed in spinal cord MNs that survive at 
the end stage of disease. Moreover, the HSPB8–BAG3–HSP70 
complex maintains granulostasis, which avoids conversion 
of dynamic stress granules (SGs) into aggregation-prone 
assemblies. We will perform a randomised clinical trial (RCT) 
with colchicine, which enhances the expression of HSPB8 and 
of several autophagy players, blocking TDP-43 accumulation 
and exerting crucial activities for MNs function.
Methods and analysis Colchicine in amyotrophic lateral 
sclerosis (Co-ALS) is a double-blind, placebo-controlled, 
multicentre, phase II RCT. ALS patients will be enrolled in 
three groups (placebo, colchicine 0.01 mg/day and colchicine 
0.005 mg/day) of 18 subjects treated with riluzole; treatment 
will last 30 weeks, and follow-up will last 24 weeks. The 
primary aim is to assess whether colchicine decreases 
disease progression as measured by ALS Functional Rating 
Scale - Revised (ALSFRS-R) at baseline and at treatment 
end. Secondary aims include assessment of (1) safety and 
tolerability of Colchicine in patiets with ALS; (2) changes in 
cellular activity (autophagy, protein aggregation, and SG and 
exosome secretion) and in biomarkers of disease progression 
(neurofilaments); (3) survival and respiratory function and (4) 
quality of life. Preclinical studies with a full assessment of 
autophagy and neuroinflammation biomarkers in fibroblasts, 
peripheral blood mononuclear cells and lymphoblasts will be 
conducted in parallel with clinic assessment to optimise time 
and resources.
Ethics and dissemination The study protocol was approved 
by the Ethics Committee of Area Vasta Emilia Nord and by 
Agenzia Italiana del Farmaco (EUDRACT N.2017-004459-21) 
based on the Declaration of Helsinki. This research protocol 
was written without patient involvement. Patients’ association 
will be involved in disseminating the study design and results. 
Results will be presented during scientific symposia or 
published in scientific journals.
trial registration number EUDRACT 2017-004459-21; 
NCT03693781; Pre-results.
strengths and limitations of this study
 ► Amyotrophic lateral sclerosis (ALS) is a rare and 
devastating disease without an effective treatment 
so far; this urgent gap can be filled with a multi-
centre randomised controlled trial (RCT) that can 
give reliable data on candidate molecules.
 ► Colchicine in ALS is going to be a randomised clinical 
trial using a drug (colchicine) that potentially targets 
multiple complex mechanisms involved in ALS, such 
as autophagy and inflammation, with the potential of 
slowing disease progression, but the possible limita-
tion that we might not be able to understand which 
specific process prevaricates in disease initiation 
and then progression.
 ► The absence of reliable biomarkers for disease pro-
gression and drug efficacy is an important target to 
be addressed in ALS; the study will give inference 
to possible biomarkers of disease progression (neu-
rofilaments and neuroinflammation biomarkers) and 
will allow in vivo search of colchicine-driven modifi-
cations of disease (study of autophagy process, pro-
tein aggregation, exosomes  and mRNA) compared 
to placebo arm, which can widen knowledge about 
ALS pathogenesis.
 ► Colchicine is an already approved drug, with known 
pharmacokinetics and safety, which is already avail-
able, and therefore there is significant possibility of 
transferability to patients and of a rapid translation 
to daily clinics.
 ► This short study will optimise time and resources to 
get reliable information for a following larger phase 
III RCT.
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INtrODUCtION 
background and rationale
Amyotrophic lateral sclerosis (ALS) is characterised by 
progressive degeneration of motor neurons (MNs) in 
both brain and spinal cord leading to progressive muscle 
weakness, relentless disability and death within 3–5 
years from symptom onset.1 The entire motor system is 
involved, determining impairment of movement, commu-
nication, feeding and respiration, with patients needing 
ventilatory and nutritional support to survive. Disease 
usually starts focally in bulbar and spinal sites of onset 
and spreads to other body regions in a heterogeneous 
way among patients, according to different phenotypes 
having dissimilar prognosis.2 Besides classic and bulbar 
ALS, flail arm, flail leg, upper motor neuron predomi-
nant (UMN-p) phenotypes are characterised by unusually 
long survival, compared with respiratory phenotype by a 
very short clinical course.
If considerable heterogeneity characterises disease 
progression, a prognostic biomarker of disease is still 
lacking. Riluzole, the first drug approved for the disease, 
prolongs survival by a mean of 3 months,3 while edara-
vone, currently available in some countries, shows limited 
effects in slowing the pace of disease progression.4 More 
than 50 randomised controlled trials (RCTs) of proposed 
disease-modifying drugs have failed to show positive 
results in the past half-century, and the reasons for this 
failure have been classified into three categories: trial 
rationale and preclinical study results, pharmacological 
issues, RCT design and methodological issues.5 Revised 
Airlie House Consensus Guidelines for design and 
implementation of ALS clinical trials have been recently 
assembled.6
From a pathological point of view, protein aggre-
gates into neurons, and glial cells are common features 
of the different ALS forms. Such aggregates include 
proteins encoded by genes that cause ALS when mutated 
(SOD1, TDP-43, FUS, SQSTM1/p62, VCP, UBQLN2, 
OPTN encoded by SOD1, TARDBP, FUS, SQSTM1, VCP, 
UBQLN2 and OPTN genes, respectively). The protein 
quality control (PQC) system has a crucial role in dealing 
with the above-mentioned aggregates, in particular with 
TDP-43 proteinopathy, which is a hallmark of more than 
95% of non-mutated ALS cases.7
The PQC system is based on chaperones and degrada-
tive pathways, which include the ubiquitin–proteasome 
systems (UPSs), the autophagy and the endoplasmic 
reticulum-associated degradation (ERAD). Disruption of 
autophagy in the brain results in inclusion bodies with 
ubiquitinated proteins and early neuronal death.8 In 
ALS, several gene products have links with protein degra-
dation pathways as they contribute to recruitment of 
ubiquitinated proteins to the autophagosome: UBQLN2, 
VCP, OPTN and SQSTM1/p62 function as adapters that 
deliver polyubiquitinated proteins to the proteasome or 
the autophagosome for degradation. OPTN serves as 
a receptor for autophagy, and VCP has a role in ERAD 
and sorting endosomal proteins, in autophagy and UPS. 
Protein aggregation and autophagy inhibition may also 
induce clearance of pathological TDP-43 via secretion of 
exosomes, small extracellular vesicles, which may play a 
key role in TDP-43 aggregate disposal and/or the propa-
gation of TDP-43 proteinopathy.8
Autophagy is also required for the removal of aberrant 
stress granules (SGs),9 10 which have been involved in ALS 
pathology. Finally, in ALS models and patients, activa-
tion of inflammasome complexes in both astrocytes and 
microglia is critically involved in neuroinflammation.11 
There is a crosstalk between autophagy and neuroinflam-
mation: autophagy downregulates inflammasome activity, 
which is activated in response to cellular inclusions 
formation,12 and TBK1, OPTN and SQSTM1/p62 gene 
products converge on autophagy and neuroinflamma-
tion, suggesting that compounds addressing both path-
ways may be promising for ALS treatment.
Preliminary data
With our study, we aim to assess the role of colchicine 
as a therapeutic agent for ALS. Colchicine is a Food and 
Drug Administration-approved drug that we identified 
in a high-throughput screening performed by using the 
promoter region of the gene encoding for a specific 
chaperone, the heat shock protein B8 (HSPB8).13
HSPB8 acts in conjunction with the co-chaperone 
Bcl2-associated athanogene 3 (BAG3), and the HSPB8–
BAG3–HSP70 complex enhances the intracellular clear-
ance of all motor neuron disease-associated misfolded 
proteins tested so far.14–16
The role of HSPB8 in the stress response in ALS has 
been elucidated in animal models and humans, indi-
cating that HSPB8 is upregulated in the spinal cord of 
patients with ALS and in surviving MNs of ALS mice.15 17
In mutant models of ALS, HSPB8 recognises and 
promotes the removal of the misfolded mutant SOD1 
and TDP-43 fragments, as well as aggregating dipep-
tides produced in C9ORF72-related neurodegenerative 
diseases, by promoting their autophagic removal from 
MNs.18–20
As for sporadic ALS, HSPB8 counteracts accumulation 
of TDP-43 and its C-terminal fragment of 25 KDa (TDP-
25), which is highly aggregation-prone due to the presence 
of a prion-like domain.13 19 20 In stress conditions, caspase 
cleavage of TDP-43 generates TDP-35 and TDP-25 frag-
ments. TDP25 loses one of the RNA recognition motifs 
and the nuclear localisation sequence (NLS), but retains 
the nuclear exportation sequence, and as a consequence, 
it mislocaliszes into the cytoplasm, inducing the formation 
of p62 bodies, a characteristic of sporadic ALS.21 The over-
expression of HSPB8 promotes the clearance of TDP-43 
and both TDP disease-associated fragments, and induces 
a decrease of cytoplasmic TDP-25 aggregates, while its 
silencing had opposite effects.13 21 22 Upregulation of the 
fly homologue of human HSPB8 protected against the 
toxicity mediated by TDP-35 and by an NLS-mutant form 
of TDP-43 that mislocaliszes into the cytosol in Drosophila 
melanogaster.19
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Finally, HSPB8-BAG3-HSP70 maintains the so-called 
‘granulostasis’, a surveillance mechanism that avoids the 
conversion of dynamic SGs into aggregation-prone assem-
blies.1 23 24
Collectively, these data establish that HSPB8 has a 
crucial activity for MN function and exerts a protective 
role against misfolded protein accumulation in cells.
Colchicine is an inexpensive drug with strong anti-in-
flammatory effects, approved for the treatment of gout 
and familial Mediterranean fever. In addition, colchi-
cine is used for the treatment of several other diseases, 
including Behçet’s disease, primary biliary cirrhosis 
and pericarditis.25 It has been proposed that colchicine 
interferes with intracellular assembly of inflammasome 
complex present in neutrophils and monocytes by inhib-
iting the nucleotide-binding domain, leucine-rich-con-
taining family, pyrin domain-containing-3 and decreasing 
the serum levels of functional interleukin (IL)−1b and 
IL-2.26
Recent studies show that colchicine induces HSPB8 
mRNA and protein expression levels, independently 
from the heat shock factor 1 (HSF1) and from BAG1 
and BAG3.13 Colchicine could also upregulate other 
proteins involved in autophagy, including the master 
regulator transcription factor EB (TFEB), the TFEB 
regulated adaptor protein SQSTM1/p62 and autophagy 
player microtubule-associated protein 1A/1B-light chain 
3 (LC3). TFEB activates autophagy but does not induce 
HSPB8 expression, which is thus upregulated by colchi-
cine in a TFEB-independent manner.
These proteins act synergistically, as TFEB stimu-
lates autophagy, while HSPB8 (with BAG3) recognises 
misfolded proteins facilitating SQSTM1/p62-mediated 
insertion into newly formed LC3-II-activated autophago-
somes. The concomitant induction of TFEB and HSPB8 
mediated by colchicine might thus lead to enhanced 
clearance of misfolded species of TDP-43 and its 25 KDa 
fragment, whose accumulation is involved in sporadic 
forms of ALS.13
Colchicine may thus exert protective effects by simul-
taneously acting on inflammation and autophagy. Based 
on these premises, we are going to perform a clinical trial 
with colchicine, which enhances the expression of HSPB8 
and of autophagy players,13 thereby blocking TDP-43 
accumulation in neuronal cells. Our study will contribute 
to the pharmacological research in ALS and will elucidate 
the implication of changes in autophagy and inflamma-
tion during disease, through a full assessment of biolog-
ical markers of autophagy and inflammation.
MEtHODs AND ANALYsIs
This multicentre, randomised, double-blind, placebo-con-
trolled, phase II study is meant to compare the efficacy, 
biological effects and safety of colchicine in combination 
with riluzole for a 30-week treatment period in patients 
with ALS.
study design
The trial was designed following the guidelines on clin-
ical investigation of medicinal products for the treatment 
of ALS provided by the European Medicines Agency and 
adopted by the Agenzia Italiana del Farmaco (AIFA), 
according to Standard Protocol Items for Randomized 
Trials statement guidelines. Protocol (version 2, 26 June 
2018) was approved by competent authorities (Comitato 
Etico Area Vasta Emilia Nord in September 2018 and 
AIFA in August 2018).
Nine specialised ALS centres will recruit patients for 
the trial and four laboratories will be in charge for biolog-
ical outcome measures (Table 1).
Figure 1 shows the design of the study.
Eligibility criteria
Study population will include patients with a probable 
laboratory-supported, clinically probable or definite ALS 
according to revised El Escorial criteria (sporadic and 
unmutated).27
To reduce phenotypic variability, we will exclude from 
the study flail arm, flail leg, UMN-p, respiratory and 
primary lateral sclerosis, and progressive muscular 
atrophy, which are characterised by a longer survival, and 
we will include only bulbar or classic phenotypes in an 
attempt to reduce disease progression heterogeneity.
The following definitions according to Chiò et al28 
should be considered for classic and bulbar phenotypes:
1. Classic phenotype is characterised by onset of symp-
toms in the upper or lower limbs, with clear but not 
predominant pyramidal signs associated with lower 
MN signs.
2. Bulbar phenotype patients have a bulbar onset with 
dysarthria and/or dysphagia, tongue wasting, fascic-
ulation and limited spinal involvement for the first 
months after symptom onset. Pyramidal signs are not 
required to be evident at the beginning but need to be 
evident thereafter.
To further reduce disease progression heterogeneity, 
we will stratify patients according to progression rate (ΔFS 
> or <0.7).29 Patients’ inclusion and exclusion criteria are 
shown in table 2.
Use of highly effective contraceptive measures 
according to Clinical Trial Facilitation Group (CTFG) 
criteria (http://www. hma. eu/ ctfg. html) is mandatory 
both for men and women.
randomisation
Eligible patients will be sequentially allocated to the 
three arms with a 1:1:1 ratio by using a computer-gener-
ated list of random numbers that will be centrally gener-
ated in the statistical unit of the University of Modena. 
After the investigators obtain the person’s consent, they 
will connect to a website dedicated to the study, in which 
the randomisation sequence is concealed.
The randomisation unit will share the randomisation list 
exclusively to an authorised company (Eclisse—Euromed 
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Table 1 Centres and facilities involved in the study  
Centre Role and activity PI responsible Work package
Azienda Ospedaliero 
Universitaria dì Modena 
(sponsor)
ALS centre, coordinating 
centre and enrolling centre
Dr Jessica Mandrioli Coordination of the trial through 
monitoring of the centers' activities, 
facilitating communication, promoting 
exchange of ideas and methodological 
approach, and stimulating analysis and 
integration of results; organisation of 
kick-off meeting and regular meetings 
with partners; submission to ethical 
committees; selection of an independent 
contract research organisation for study 
monitoring; case report form (CRF) creation 
with statistics unit;  establishment of an 
independent DSMB
Patients’ enrolment and follow-up as 
specified for enrolling centres (see row 
below), and presentation and dissemination 
of results
University of Turin ALS centre and enrolling 
centre
Professor Adriano 
Chiò
Each centre is expected
 ► To randomise at least six patients 
fulfilling including and excluding 
criteria in a period of 12 months and to 
administer the treatment for 30 weeks.
 ► To provide one PI and one 
neurologist to evaluate including and 
excluding criteria, administer treatment, 
and assess primary and secondary 
outcomes.
 ► To formally adhere to the practice 
parameters of the European Federation 
of Neurological Societies concerning 
the standardisation of the management 
of the patient in terms of ventilatory 
support and nutrition.
 ► To process, store and send biological 
samples to facilities as established by 
the protocol.
Istituto Auxologico, University 
of Milan
ALS centre and enrolling 
centre
Professor Vincenzo 
Silani
IRCCS Mondino Foundation ALS cCentre and enrolling 
centre
Professor Mauro 
Ceroni
University of Bari ALS centre and enrolling 
centre
Professor Isabella 
Laura Simone
IRCCS San Raffaele Institute 
of Milan
ALS centre and enrolling 
centre
Dr Nilo Riva
Neuromuscular OmniCentre, 
Rome, Catholic University, 
Rome
ALS centre and enrolling 
centre
Dr Mario Sabatelli
Universita’ dì Napoli ‘L. 
Vanvitelli’
ALS centre and enrolling 
centre
Dr Maria Rosaria 
Monsurro
University of Padova ALS centre and enrolling 
centre
Dr Gianni Soraru
University of Modena and 
Reggio Emilia,
Modena
Statistics unit Professor Roberto 
D’Amico
CRF creation with coordinating unit, 
randomisation, data extraction, 
statistical analysis, periodical reports to 
DSMB; presentation and dissemination of 
results
Center of Excellence on 
Neurodegenerative
Diseases, University of Milan
Laboratory of experimental 
biology
Professor Angelo 
Poletti
Autophagy process (mRNA and protein 
levels of p62, LC3, TFEB, ATGs, HSPB8, 
BAG3, BAG1, HSP70 and HSF1) in 
lymphoblasts, fibroblasts and muscle cells; 
levels and relative ratio between soluble 
and insoluble species of TDP-43 and TDP-
43 fragments, SQSTM1/p62, UBQLN and 
OPTN in lymphoblasts and fibroblasts
IRCCS Mondino Foundation, 
Pavia
Genomics and 
postgenomics centre
Dr Cristina Cereda Sample collection and preparation for other 
laboratories, study of colchicine effects 
on RNA profile on PBMCs and fibroblasts 
of patients, study of colchicine effects 
on extracellular vesicles and biomarkers 
of neurodegeneration (phosphorylated 
neurofilament heavy chain) in plasma
Continued
5Mandrioli J, et al. BMJ Open 2019;9:e028486. doi:10.1136/bmjopen-2018-028486
Open access
Clinical Supply Services Srl, Cantù (Como), Italy; http://
www. css. euromed. it/ en/) responsible for the preparation 
of investigational drug and placebo.
All patients will receive a unique patient identifica-
tion number at the screening visit when signing the 
informed consent and before any study procedures are 
performed. This number will be used to identify the 
patient throughout the study. The patient identification 
number will remain constant throughout the entire study.
Fifty-four patients will be randomised in the following 
three groups:
 ►  Eighteen patients will receive colchicine 0.01 mg/kg/
day+riluzole.
 ► Eighteen patients will receive colchicine 0.005 mg/
kg/day+riluzole.
 ► Eighteen patients will receive placebo+riluzole.
stratification
Patients will be stratified according to ΔFS (</≥0.7).29 
The investigator will randomise patients directly online. 
In case of discontinuation from the study, the randomisa-
tion number will not be reused.
Experimental drug preparation, dispensation and blinding 
procedures
The investigational medical product (IMP) will be pack-
aged and labelled according to current Good Manufac-
turing Procedure guidelines, Good Clinical Practice 
(GCP) guidelines and national legal requirements by an 
authorised company (Eclisse). The package given to the 
patient will have a tear-off part that will be removed at 
the time of dispensation by the investigator and attached 
to the study documents. Treatment and placebo will be 
made indistinguishable by Eclisse.
The investigator will be provided with technical options 
and password information to selectively break the code for 
an individual patient by telephone, or through electronic 
message transfers. The premature breaking of the code 
will be confined to emergency cases in which knowledge 
of the administered drug is necessary for adequate treat-
ment. Should any code be broken, the respective patient 
will be withdrawn from further participation in the study.
The investigator or pharmacist will receive numbered 
treatments and will be responsible for safe and proper 
handling and storage of the IMP at the investigational 
site. All remaining IMPs, used and unused, will be 
collected and returned for destruction during the study, 
and Eclisse will be responsible for IMP manufacture and 
logistics services, including preparation of randomisation 
list, envelopes, packaging and labelling, storage, ship-
ment and destruction of the product.
Centre Role and activity PI responsible Work package
University of Modena 
andReggio Emilia, Modena
Laboratory of molecular 
biology
Professor Serena 
Carra
Identification of changes in stress granule 
response and composition in patients’ 
fibroblasts and lymphoblasts; identification 
of changes in proteotoxic stress response 
and accumulation of aggregated proteins 
in the cytoplasm and nucleus, including 
compartmentalisation and clearance of 
defective ribosomal products
Istituto di Ricerche 
Farmacologiche Mario Negri, 
IRCCS, Milan
Laboratory of translational 
biomarkers
Dr Valentina Bonetto Samples collection, study of colchicine 
effects on extracellular vesicle secretion in 
cerebrospinal fluid (CSF) using biochemical 
profiling, analysis of biomarkers of 
neurodegeneration (phosphorylated 
neurofilament heavy chain in CSF) and 
neuroinflammation (IL-18, IL-18BP, MCP1 
and IL-17 in plasma and CSF)
ALS, amyotrophic lateral sclerosis; CRF, case report form; CSF, cerebrospinal fluid; DSMB, data and safety monitoring board; HSF1, heat s  
hock f  actor 1; HSP, heat shock protein;  IL, interleukin; IRCCS, Istituto di Ricoveroe Cura a Carattere Scientifico; LC3, light chain 3; PBMC, 
peripheral blood mononuclear cell; PI, principal  investiga  tor; TFEB, transcription factor EB. 
Table 1 Continued 
Figure 1 Design of the study. FS, progression rate; 
IVRS, interactive voice response system; IWRS, interactive 
web response system.  
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study treatment administration
Subjects enrolled will receive a total daily dose of 1 or 0.5 
or 0.25 mg colchicine, depending on body weight (cut-
off: 70 kg) and treatment arm, or a matching placebo, to 
be taken in the morning and in the evening at fasting 
(>3 hours), as indicated in table 3, a and b. Patients will 
be instructed to bring their used and unused IMP at each 
visit. Compliance will be assessed by the investigator by 
Table 2 Inclusion and exclusion criteria    
Inclusion criteria Exclusion criteria
 ► Patients diagnosed with a laboratory-supported, 
clinically ‘probable’ or ‘definite’ ALS according to the 
Revised El Escorial criteria.
 ► Sporadic ALS.
 ► ALS phenotypes: classic or bulbar.
 ► Female or male patients aged between 18 and 80 years 
old.
 ► Disease duration from symptom onset no longer than 
18 months at the screening visit.
 ► Patients treated with a stable dose of riluzole (100 mg/
day) for at least 30 days prior to screening.
 ► Patients with a weight of >50 kg and a BMI of ≥18.
 ► Patients with an FVC ≥65% predicted normal value for 
gender, height and age at the screening visit.
 ► Patients able and willing to comply with study 
procedures as per protocol.
 ► Patients able to understand and capable of providing 
informed consent at screening visit prior to any 
protocol-specific procedures.
 ► Use of highly effective contraception for both men and 
women.
 ► Prior use of colchicine.
 ► Prior allergy/sensitivity to colchicine.
 ► Receiving colchicine or other anti-inflammatory drugs (such as 
corticosteroids, methotrexate, antineoplastic, interleukin 1–1b 
antagonist, tumor necrosis factor-alpha inhibitor).
 ► Receiving food or comedications, such as strong–moderate 
cytochrome P450 3A4 inhibitors that will result in elevated plasma 
levels of colchicine.
 ► Inflammatory disorders (systemic lupus erythematosus, rheumatoid 
arthritis and connective tissue disorder), chronic infections (HIV and 
hepatitis B or C infections) or significant history of malignancy.
 ► Severe renal (estimated Glomerular Filtration Rate  <30 mL/min/1.73 m2) 
or liver failure or liver aminotransferase (aspartate transaminase/ 
alanine transaminase >2× upper limit of normal).
 ► Existing blood dyscrasia (eg, myelodysplasia).
 ► White blood cells <4 x 109/L, platelets count of <100 x 109/L and 
hematocrit level of <30%.
 ► Severe comorbidities (heart, renal and liver failures), autoimmune 
diseases or any type of interstitial lung disease.
 ► Patients who underwent non-invasive ventilation, tracheotomy and/
or gastrostomy.
 ► Women who are pregnant or breastfeeding.
 ► Participation in pharmacological studies within the last 30 days before 
screening.
 ► Patients with the following ALS phenotypes: flail arm, flail leg, UMN-p, 
respiratory PLS and progressive muscular atrophy.
 ► Patients with familial ALS defined as the presence of at least one first-
degree family member (parents/son/daughter/brother/sister) affected 
by ALS.
 ► Patients with known pathogenic mutations (SOD1, TARDBP, FUS and 
C9ORF72).
ALS,  amyotrophic lateral sclerosis; BMI, body mass index; FVC, forced vital capacity; UMN-p, upper motor neuron predominant; 
PLS, primary lateral sclerosis. 
Table 3 Doses of colchicine according to treatment arm and weight: (a) treatment arm colchicine 0.01 mg/kg/day, (b) 
treatment arm colchicine 0.005 mg/kg/day and (c) dose reduction steps
Patient’s weight (kg) Daily dose (mg) Before breakfast Before dinner
0.01 mg/kg/day
  ≤70 0.5 mg 1 tablet (0.5 mg) of AT 1 tablet (0.5 mg) of P
  >70 1 mg 1 tablet (0.5 mg) of AT 1 tablet (0.5 mg) of AT
0.005 mg/kg/day
  ≤70 0.25 mg 1 tablet (0.5 mg) of AT every other day 1 tablet (0.5 mg) of P
  >70 0.5 mg 1 tablet (0.5 mg) of AT 1 tablet (0.5 mg) of P
Starting dose (mg/day)
First dose reduction 
(mg/day) Second dose reduction (mg/day)
Third dose reduction 
(mg/day)
  1 0.5 0.25 Stop
  0.5 0.25 Stop
  0.25 Stop
AT, active treatment; P, placebo.
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counting the remaining tablets returned by the patient. 
Dose reductions may be necessary in case of toxicities 
or overdoses, which will be monitored at each visit; this 
request will be made by online CRF through extradis-
pensation or at drug dispensation. The system will auto-
matically perform dose escalation according to the initial 
dose of colchicine or matching placebo, as depicted in 
table 3, c.
Primary objective
The primary objective is to assess whether different 
colchicine doses decrease disease progression, measured 
through ALS Functional Rating Scale—Revised (Italian 
version), in patients with ALS compared to the control 
arm and measured at baseline and at week 30 (treatment 
end).
secondary objectives
Colchicine safety and tolerability in ALS
It will be assessed by periodic monitoring of possible 
adverse events (AEs), the most common being diarrhoea, 
abdominal cramping and pain, nausea and vomiting. 
These events are often the first signs of toxicity and may 
indicate the need for dose reduction or therapy discon-
tinuation; a plan for dose reduction will be shared by 
all clinicians. Other known AEs that will be monitored 
are pharyngolaryngeal pain (reported in 1%–10%); 
blood cells alterations (<0.1%); peripheral neurop-
athy, myopathy, rhabdomyolysis, elevated creatine phos-
phokinase (CPK) and muscle pain (<0.1%); alopecia, 
delayed corneal wound healing, hypersensitivity and 
azo-/oligospermia (<0.1%); and rashes, urticaria, derma-
titis, renal damage, hepatic damage and loss of appetite 
(<0.01%). Death from any cause or tracheotomy will be 
considered as a serious adverse event (SAE).
Biological assessment
We expect to find that colchicine increases the expression 
of inducers, markers and chaperones of the autophagy 
process, with a consequent reduction of accumulation 
of TDP-43; ALS-associated TDP-43 fragments; insoluble 
forms of SQSTM1/p62, UBQLN and OPTN; changes in 
extracellular vesicle secretion, as well as a decrease in the 
stress response. Colchicine action will be studied in fibro-
blasts, peripheral blood mononuclear cells (PBMCs) and 
lymphoblasts.30–32
Specific biological targets to be looked for between 
colchicine and placebo arms at baseline and at the end of 
treatment include
 ► Quantification of mRNA and protein levels of p62, 
LC3, TFEB, ATGs, HSPB8, BAG3, BAG1, HSP70 
and HSF1 in patients’ PBMCs, lymphoblasts and 
fibroblasts (transcriptome profile)33; we will test this 
profile also in available muscle biopsy (optional for 
patients); particular attention will be paid to possible 
formation of autophagic vacuoli, which may resemble 
those identified in inclusion body myopathy, Paget 
disease of bone with Frontotemporal Dementia 
(IBMPFD) and ALS possibly associated with auto-
phagy hyperactivation.34
 ► Identification of changes in SG response and compo-
sition in patients’ fibroblasts and lymphoblasts.
 ► Assessment of the overall levels and the relative 
ratio between soluble and insoluble species of 
TDP-43, TDP-43 fragments, SQSTM1/p62, UBQLN 
and OPTN in fibroblasts, PBMCs and lymphoblasts.
 ► Determination, using buffers with increasing deter-
gent power (phosphate-buffered saline, Triton-X100, 
sodium dodecyl sulfate  and formic acid), of which 
form of the insoluble species of the proteins tested 
above is detectable after treatment.
 ► Study of colchicine effects on extracellular vesicle 
secretion in blood and cerebrospinal fluid (CSF). 
Analysis of TDP-43, hyperphosphorylated TDP-43, 
SQSTM1/p62, UBQLN and OPTN in extracellular 
vesicles derived from plasma and CSF.35
 ► Colchicine effects on peripheral and CSF biomarkers: 
creatinine, albumin, CK and vitamin D in plasma as 
markers of disease severity; phosphorylated neurofil-
ament heavy chain in CSF and plasma as marker of 
neurodegeneration; plasma/CSF IL-18, its endoge-
nous inhibitor IL-18BP, MCP1 and IL-17 as markers 
of inflammation.
If the data will reveal the existence of highly responsive 
patients (with an ALS Functional Rating Scale - Revised 
(ALSFRS-R) decline of ≤2 points in 30 weeks), the anal-
ysis of the effect of colchicine will then be replicated 
in induced pluripotent stem cells (iPS) cells derived from 
a selected subset of patients enrolled in the study (either 
from PBMCs or fibroblasts). The iPS cells will be differ-
entiated to motoneuronal cells to determine whether the 
effects of colchicine evaluated in blood and skin cells will 
be replicated in ‘bona fide’ MNs.
Clinical assessment
Periodic clinical assessment will be performed at defined 
time points by
 ► Overall survival from randomisation to date of docu-
mented death or tracheostomy or non invasive venti-
lation (NIV)>22 hours/day.
 ► Survival rate at weeks 30, 42 and 54.
 ► Forced vital capacity score from baseline to weeks 8, 
18, 30, 42 and 54.
Quality of life assessment
Determination of quality of life as perceived by patients 
with ALS will be investigated by comparing ALS assess-
ment questionnaire (ALSAQ-40) from baseline to weeks 
8, 30 and 54.
Table 4 shows study procedures to be undertaken (study 
flow chart).
sample size calculation
ALS progression will be assessed through the ALSFRS-R. 
It has been reported that ALS caring neurologists 
consider of clinical significance a difference of 4 points 
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Table 4 Study flow chart
Examinations
Pre-treatment Treatment
Treat-
ment end Follow-up
Study 
end
Screening 
(VS)
Baseline 
(W0) W1
W2, W6, 
W10, 
W14, W16
W4,
W8,
W12
W18, 
W24 W30 W36 W42 W54
Time window <1 week 
from 
screening
±1 day ±1 day ±2 days ±2 days ±3 days ±5 days ±5 days ±7 days
Informed consent x
Medical history x
Inclusion exclusion criteria x
Patient able to understand 
and follow the patient card 
procedures
x
Phone call x
Clinical assessment
Neurological examination x X x x x x x x x
ALSFRS-R x X x x* x x x x x
FVC x X x* x x x x
MRC x X x* x x x x
BMI x X x x x x x x x
Safety assessment
Adverse events X x x x x x x x x
Vital signs x X x x x x x x x
Physical examination x x x x x x x x x
Chest X-ray x
ECG x
Abdominal US x
Hematology x x x* x x x x
Biochemistry x x x* x x x x
Urinalysis x x x
Pregnancy test x X† x X† X
Infectious markers x
Biological activity
Autophagy on lymphoblasts x x x
Autophagy on fibroblasts x x
Autophagy on muscle cells x‡ 
Stress granule response on 
lymphoblasts
x x x
Stress granule response on 
fibroblasts
x x
Aggregates accumulation on 
lymphoblasts
x x
Aggregates accumulation on 
fibroblasts
x x
RNA-seq on PBMCs/fibroblasts x x
Plasma extracellular vesicles and 
neurodegenerationbiomarkers
x x x
CSF extracellular vesicles and 
neurodegenerationbiomarkers
x x
Neuroinflammationmarkers 
(IL18, IL-18BP, MCP1 and IL17 in 
plasma and CSF).
X
PBMCs/fibroblasts differentiation 
to iPS cells and MNs
x
Continued
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in the decline of ALSFRS-R, and that patients with ALS 
have on average an ALSFRS-R decline of 0.89 points/
month (SD:0.13).36–38 Therefore, we can consider a 
mean ALSFRS-R decline in 30 weeks of 6.23, with 90% of 
patients presenting a decline of the ALSFRS-R total score 
ranging from 4.7 to 7.7.
As a result, for this study, during the 30 weeks of treat-
ment, we will expect that the minority (10%) of patients 
with ALS will not have a decline at ALSFRS-R of at least 4 
points from baseline, whereas a relevant number of those 
treated, that we quantify in a maximum of 60%, will not 
have the same decline. In other words, we expect that after 
30 weeks of treatment the percentage of positive response 
in the control group will be equal to 10%, whereas in the 
experimental group it will be equal to 60%.
The null hypothesis is that the percentage of positive 
response (increase of ALSFRS-R <4 points at 30 weeks) 
between Colchicine and placebo groups will not differ 
after 30 weeks of treatment.
The alternative hypothesis is that Colchicine determines 
an increase of positive response compared to placebo of 
at least 50%, in absolute scale (60% vs 10%).
The study has been designed to reject the null hypoth-
esis with an alpha error of 0.025 (to take into account a 
multiple comparison with a control arm) and a power of 
0.80. For this purpose, a sample of 51 patients randomised 
in 3 arms would be needed. Considering an average drop 
out of 5%, a recruitment of 54 patients will be necessary.
Concomitant medications and concerns
All medications taken by the patients at the onset of study 
and all medication given in addition to the IMP during 
the study will be regarded as concomitant medications.
Colchicine is available in an oral formulation (tablet with 
strength of 1 mg) with well-known pharmacokinetics, toxi-
cology and dynamics. It has a bioavailability of 45%, with 
onset at 18–24 hours, time to peak effect at 48–72 hours, 
and peak plasma concentration of 6.2–6.8 ng/mL. 
The drug is metabolised by P-gp and CYP3A4, and it is 
demethylated to two primary metabolites and one minor 
metabolite. Half-life is reported to be within 26 and 
31 hours and excretion occurs through feces and urine 
(65%).
Inducers of CYP3A4 and P-gp may decrease Colchi-
cine concentrations whereas inhibitors of CYP3A4 and 
P-gp may increase Colchicine concentrations. To avoid 
toxicity, strong CYP3A4 and P-gp inhibitors will be 
prohibited as well as bitter oranges intake. Concomitant 
use of strong inducers (eg, rifampin, rifabutin) will be not 
recommended.
Colchicine contains lactose. Patients with rare heredi-
tary problems of galactose intolerance, the Lapp lactase 
deficiency or glucose-galactose malabsorption should not 
take this medication. Among other drug or substances to 
be alerted:
 ► Ciclosporin: possible increased risk of nephrotoxicity 
and myotoxicity.
 ► Vitamins: the absorption of vitamin B12 may be 
impaired by chronic administration or high doses of 
Colchicine; if required vitamin supplementation may 
be increased.
 ► Statins: acute myopathy has been reported in patients 
given Colchicine with statins.
 ► Grapefruit Juice: it strongly inhibits the CYP3A4-me-
diated metabolism of Colchicine, therefore it is 
forbidden.
Data analysis plan
Separate analyses will be performed in:
1. All randomised subjects receiving at least 1 dose of 
study medication (intention-to-treat population);
2. All randomised subjects excluding protocol deviations 
(Per protocol, PP population).
Descriptive statistics
Descriptive statistics will be performed comparing the 
groups of Colchicine treatment and placebo.
Continuous variables will be described using mean 
and SD or median and IQR; categorical variables will be 
described as counts and percentages.
Examinations
Pre-treatment Treatment
Treat-
ment end Follow-up
Study 
end
Screening 
(VS)
Baseline 
(W0) W1
W2, W6, 
W10, 
W14, W16
W4,
W8,
W12
W18, 
W24 W30 W36 W42 W54
Quality of life assessment
ALSAQ-40 x x§ x x
Study treatment dispensation and compliance
Study treatment dispensation x x x
Study treatment compliance x x x x
Concomitant medications x x x x x x x x x x
*Only at week 4 and 12.
†Pregnancy test has to be performed every month for fertile women (week: 4-8-12-16-20-24-28-30).
‡Muscle biopsy is optional for patients. 
§Only at week 8 . 
Table 4 Continued 
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Colchicine efficacy
The comparison of positive responses (as defined above) 
among arms will be carried out by using the logistic 
regression model. Results will be presented as ORs and 
95% CI.
Biological activity
Mean differences in plasma and CFS concentrations of 
different biomarkers from baseline to week 30 will be 
calculated and compared using t-test or Wilcoxon-Mann-
Whitney test.
The mean cellular biomarkers change over time will 
be assessed using repeated measures analysis of variance 
(ANOVA), with treatment as between-subjects factor 
and time as within-subjects factor. Different models will 
be used, each with a different biomarker of activity as 
the dependent variable. Models will be adjusted for any 
unbalanced distribution of the main prognostic factors 
(eg, age) between the treatment arms.
Safety analysis
Safety analysis will be performed in all subjects receiving 
at least one dose of the experimental drug. All AEs and 
SAEs will be recorded according to ICH Guidelines and 
compared in the treatment arms at any follow-up visit and 
at study end.
Differences in tracheostomy-free survival (Kaplan-
Meier method) between the treated groups and placebo 
group will be compared using the log-rank test. Cox's 
proportional hazard model would be used to adjust for 
any possible unbalanced prognostic factors. Statistical 
significance will be set at 0.05 level for a two-tailed test. 
Missing data will be handled using the last observation 
carried forward.
Adverse events
AEs, SAEs, adverse drug reaction (ADR), Unexpected 
ADR, will be defined accordingly to ‘ICH guidance for 
Clinical Safety Data Management: Definitions and Stan-
dards for Expedited Reporting’.
All AE occurring between the first study-related proce-
dure and the last study-related procedure will be reported. 
Those meeting the definition of SAE will be reported 
in an ad hoc SAE Form; they will be reported to coor-
dinating centre within 24 hours. All AE will be recorded 
in the eCRF with a diagnosis (whenever possible), and 
together with investigator’s opinion concerning the rela-
tionship of the AE to study treatment.
stopping rules for administering the drug (single patient)
The following rules will apply regardless of the relation-
ship with treatment:
 ► First occurrence of moderate AE: study treatment will 
be interrupted until AE has returned to baseline value 
or mild intensity, then resumed at the same dose level.
 ► If the same moderate AE reoccurs, study treatment 
will be interrupted until AE has returned to baseline 
or mild intensity, then resumed with a dose reduction 
(according with investigator decision).
 ► In case of severe AE, study treatment will be inter-
rupted until AE has returned to baseline level or mild 
intensity, then resumed with a dose reduction.
 ► In case of life-threatening or disabling AE, study treat-
ment will be definitely discontinued.
stopping rules for safety reasons
To establish stopping rules, we will consider the following 
list of toxicities as acceptable: diarrhea, abdominal 
cramping and pain, nausea, vomiting, pharyngolaryngeal 
pain; mild/moderate blood cells alterations; elevated 
CPK, muscle pain, alopecia, delayed corneal wound 
healing, hypersensitivity, rashes, urticaria, dermatoses, 
dermatitis (mild/moderate severity), elevated AST/ALT/
ALP, loss of appetite.
A procedure consisting of stopping the trial in case 
of excess of AE recording the treating group in case of 
25% of the occurrence of the following: agranulocytosis, 
severe thrombocytopenia, aplastic anaemia; moderate/
severe peripheral neuropathy, myopathy, rhabdomyolysis, 
renal damage, hepatic damage.
Based on the occurrence of AEs in each group (0.01 mg/
kg/day or 0.005 mg/kg/day) or other clinically signifi-
cant safety evaluations, it will be decided which dose of 
Colchicine has the best risk/benefit ratio to conclude for 
further studies.
EtHICs AND DIssEMINAtION
The study will be carried out in accordance with the 
Declaration of Helsinki, as amended by the 64th WMA 
General Assembly, Fortaleza, Brazil, October 2013.
All subjects will sign and personally date an approved 
Informed Consent (IC) Form after receiving detailed 
written and verbal information about the reason, the 
nature, the required procedures, the intended duration 
and the possible risks and benefits and any discomfort 
associated with the study. No study procedure will be 
performed before the written IC has been provided. This 
study will be conducted in accordance with the Declara-
tion of Helsinki and the ICH E6 guideline (Good Clinical 
Practice). Both the Patient Information Sheet and the 
IC Form have been approved by the Ethics Committee 
with the study protocol. The results of the study will be 
presented during scientific symposia or published in 
scientific journals only after review and written approval 
by the involved parties in full respect of the privacy of the 
participating subjects.
An insurance company will provide insurance coverage 
for damages emerging from the trial.
Patient and public involvement
This research protocol was written without patient involve-
ment. Patients were not invited to comment on the study 
design and were not consulted to develop patient-rele-
vant outcomes or interpret the results. Patients were not 
expected to contribute to conducting this study and to 
the writing of this document for readability or accuracy. 
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Patients’ association will be involved in disseminating the 
study design at patients’ enrolment beginning, to allow 
patients to participate in it; patients’ association will be 
involved in study results dissemination not only to partic-
ipants but to the entire patient communities (eg, by 
website information)
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